These results show cancer patients with higher TF‐EVs were 7 times more likely to develop a VTE in the observational cohort than those with the same TF‐EV concentration who received enoxaparin, highlighting that LMWH might be causing a reduction of TF‐EVs [63]. This evidence concerns the gene TF and cancer.